CerroZone Receives FDA 510(k) Class II Clearance

CerroZone ™ LLC’s new mobile air purification device has earned 510(k) Class II clearance from the U.S. Food and Drug Administration as a recirculating air cleaner for eliminating airborne viruses and bacteria. The FDA approval was contingent on extensive testing at accredited independent third-party facilities.

The CerroZone mobile unit is designed to purify air in buildings such as schools, retail environments, offices, and other indoor spaces. CerroZone’s indoor system achieved a 99.998 percent reduction of live COVID-19 Delta Variant in a single pass of approximately 1.2 seconds, according to independent testing at MRI Global in Kansas City.

Unlike other solutions, the CerroZone product features patented ozone technology. “This is the first technology to truly harness the disinfecting power of ozone in a way that is safe for consumers and the environment,” said Michael Duggan, President of St. Louis, Mo.-based CerroZone. “It will fundamentally change the industry standard for air purification.”

CerroZone previously announced it had achieved Intertek’s Zero Ozone Certification. Intertek considers emissions of .005 ppm or less to be negligible per UL 2998, the North American industry standard for ozone testing. The CerroZone unit recorded at only .001 ppm.

Among its benefits to the market, the CerroZone™ platform only requires annual preventive maintenance, unlike filtration-based systems that need quarterly replacement of filters and other components.

“Today’s news further validates the exceptional quality of our system,” said Marlon Robinson, Director of Operations for CerroZone. “We knew the effectiveness of the CerroZone unit based on our prior testing, including on live COVID-19. To show similar effectiveness on a different strain reinforces that CerroZone is positioned to aid the public in the fight against emerging and future variants.”

Robinson added, “We are now ready to commercialize this amazing technology. We have been methodical in our approach, with successful field trials consistently demonstrating our product’s performance. We look forward to providing the market with an effective, proven solution including an attractive preventive maintenance schedule.”

The patented CerroZone system was developed in conjunction with Micron Pure™, a Hecto Group™ company.

CerroZone is part of the Marmon Plumbing & Refrigeration group of Chicago-based Marmon Holdings, Inc. Marmon Holdings, a Berkshire Hathaway company, is a global industrial organization comprising 11 diverse business groups and more than 100 autonomous manufacturing and service businesses.

SourceCerroZone

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.